PharmaShots | Incisive News in 3 Shots

Subscribe Now

GSK

GSK Reports the P-III (GLISTEN) Study Results of Linerixibat to Treat Primary Biliary Cholangitis (PBC) Patients with Cholestatic Pruritus

GSK Reports the P-III (GLISTEN) Study Results of Linerixibat to Treat Primary Biliary Cholangitis (PBC) Patients with Cholestatic...

November 19, 2024

GSK Provides Update on P-III (DREAMM-7) Trial of Blenrep for Treating R/R Multiple Myeloma

GSK Provides Update on P-III (DREAMM-7) Trial of Blenrep for Treating R/R Multiple Myeloma

November 14, 2024

GSK’s Ojjaara (Momelotinib) Receives the Health Canada’s Approval to Treat Myelofibrosis in Adults with Moderate to Severe Anemia

GSK’s Ojjaara (Momelotinib) Receives the Health Canada’s Approval to Treat Myelofibrosis in Adults with Moderate to Severe Anemia

November 13, 2024

GSK to Acquire Chimagen Biosciences’ CMG1A46, Expanding its Immunology Pipeline

GSK to Acquire Chimagen Biosciences’ CMG1A46, Expanding its Immunology Pipeline

October 30, 2024

GSK Enters into a 5-Year Partnership with Cambridge University to Address Kidney and Respiratory Diseases

GSK Enters into a 5-Year Partnership with Cambridge University to Address Kidney and Respiratory Diseases

October 22, 2024

GSK Reports the US FDA’s NDA Acceptance of Gepotidacin with Priority Review to Treat Uncomplicated Urinary Tract Infections

GSK Reports the US FDA’s NDA Acceptance of Gepotidacin with Priority Review to Treat Uncomplicated Urinary Tract Infections

October 16, 2024

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us